$TRNO

Terreno Realty sees rise in Q3 occupancy (TRNO:NYSE)

Terreno Realty (TRNO) reported a Q3 occupancy increase to 97.8%, up from 97.6% in Q2 and 96.2% year-over-year. The same-store portfolio, ~17.3M sq. ft., was 97.9% leased, slightly down from 98.3% in Q2.

Original reporting
Published Oct 6, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Terreno Realty sees rise in Q3 occupancy (TRNO:NYSE) — source image
Decision brief

The 30-second read

$TRNOBullishLow
01

Why it matters

The modest occupancy increase may reinforce positive sentiment but is unlikely to trigger significant trading activity.

02

Market read

A routine operating update with limited trading impact.

03

What to watch

Potential lease expirations later in the year and tenant credit quality.

Relevance 4/10Novelty 2/10Timing: same day

Background

Terreno Realty is a U.S. REIT focused on office and industrial properties. Occupancy rates are a key performance indicator for REITs.

Company-level read

Ticker impact

$TRNOBullishMedium confidence
Context

Terreno Realty reported its portfolio occupancy rose to 97.8% at end‑September, up from 97.6% in June.

Expected impact

likely modest upside as the market prices in improved leasing performance

Evidence & confidence

Occupancy improvement is a positive operating metric, but the change is incremental and not material enough to drive a sharp price move.

Market effects

May signal continued strength in the office/industrial REIT sector.

Limited to U.S. commercial real‑estate markets.

Minimal.

Counterpoint

Occupancy gains could be offset by rising interest rates affecting REIT valuations.

Key entities

  • Terreno Realty

    U.S. listed REIT (ticker TRNO).

Related articles

Med

Stifel maintains Buy rating on OrthoPediatrics, $27 price target

Stifel kept a Buy rating on OrthoPediatrics with a $27 price target, implying 13.4% upside. The company reported 18.6% revenue growth in 3Q26, exceeding estimates, and achieved positive free cash flow of $1.6 million. Management raised full-year sales guidance, indicating strong operational performance.

$CCOIHighAI 8/10

Moody’s cuts Cogent rating to Caa2 on mounting 2027 debt refinancing risks

Moody’s downgraded Cogent Communications (CCOI) to Caa2 from B2, citing liquidity concerns and refinancing risks due to $1.2B debt maturing in 2027. The rating agency noted high leverage (10x debt/EBITDA) and soft demand, but acknowledged strategic strengths like AI-driven traffic growth and potential asset monetization. CCOI's outlook is negative, with further downgrades possible if liquidity worsens.